Rare disease biotech Beren adds $300M from new financingsnews2026-06-10T18:49:16+00:00June 10th, 2026|Endpoints News|
Parabilis CEO Mathai Mammen on biotech’s record IPOnews2026-06-10T17:24:13+00:00June 10th, 2026|Endpoints News|
Novartis and Orionis strike second molecular glue deal for $40M upfrontnews2026-06-10T15:34:24+00:00June 10th, 2026|Endpoints News|
SonoThera raises $125M for non-viral gene therapy approachnews2026-06-10T15:23:43+00:00June 10th, 2026|Endpoints News|
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundationnews2026-06-10T14:01:21+00:00June 10th, 2026|Endpoints News|
Biotech pay analysis: 12 execs with $35M+ M&A golden parachutesnews2026-06-10T14:00:59+00:00June 10th, 2026|Endpoints News|
Ethyreal lands $101M to treat both Graves’ and thyroid eye diseasenews2026-06-10T11:05:38+00:00June 10th, 2026|Endpoints News|
Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studynews2026-06-10T10:37:04+00:00June 10th, 2026|Endpoints News|
Parabilis’ $670M IPO sets new biotech record, will fund cancer drugnews2026-06-10T01:21:40+00:00June 10th, 2026|Endpoints News|
Eli Lilly’s claims data deadline may kick off new 340B fightnews2026-06-09T18:38:25+00:00June 9th, 2026|Endpoints News|
